Skip to content
Study details
Enrolling now

A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)

Pfizer
NCT IDNCT07400653ClinicalTrials.gov data as of Apr 2026
Phase

Phase 3

Ages

18+

Locations

36 sites in CA, CO, FL +10

About this study

This Phase 3 study is focused on people with obesity. The primary outcome being measured is Percent Change from baseline in body weight.

Based on ClinicalTrials.gov records.

PhasePhase 3
Primary goalPercent Change from baseline in body weight

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low14%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Percent Change from baseline in body weight

Secondary: Change from Baseline in Control of Eating Questionnaire (CoEQ), Change from Baseline in Diastolic Blood Pressure (DBP), Change from Baseline in EuroQoL 5-Dimension 5-Level (EQ5D-5L), Change from Baseline in Fasting Glucose, Change from Baseline in Fasting insulin, Change from Baseline in Food Noise Questionnaire (FNQ), Change from baseline in Fasting triglycerides, Change from baseline in High-density lipoprotein cholesterol

Body systems

Endocrinology